This dual role of IL-8 highlights its potential as both a biomarker for aggressive cancer behavior and a therapeutic target, suggesting that modulating IL-8 levels could mitigate the adverse effects of bone metastases on patient morbidity [70]. This evidence concerns the gene CXCL8 and cancer.